Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

M. Svaton, M. Bratova, O. Fischer, J. Krejci, L. Koubkova, M. Cernovska, M. Hrnciarik, M. Zemanova, H. Coupkova, B. Porzer, D. Dolezal, T. Tuzova, K. Hurdalkova, M. Barinova, J. Skrickova

. 2021 ; 41 (4) : 2059-2065. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018890

BACKGROUND/AIM: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. PATIENTS AND METHODS: We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher's exact test. Overall (OS) and progression-free (PFS) survival were estimated by Kaplan-Meier method. RESULTS: ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib. CONCLUSION: Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018890
003      
CZ-PrNML
005      
20210830100454.0
007      
ta
008      
210728s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.14975 $2 doi
035    __
$a (PubMed)33813414
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Svaton, Martin $u Department of Pneumology and Phthisiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; svatonm@fnplzen.cz
245    10
$a Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study / $c M. Svaton, M. Bratova, O. Fischer, J. Krejci, L. Koubkova, M. Cernovska, M. Hrnciarik, M. Zemanova, H. Coupkova, B. Porzer, D. Dolezal, T. Tuzova, K. Hurdalkova, M. Barinova, J. Skrickova
520    9_
$a BACKGROUND/AIM: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. PATIENTS AND METHODS: We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher's exact test. Overall (OS) and progression-free (PFS) survival were estimated by Kaplan-Meier method. RESULTS: ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib. CONCLUSION: Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.
650    _2
$a dospělí $7 D000328
650    _2
$a afatinib $x terapeutické užití $7 D000077716
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x genetika $x mortalita $x patologie $7 D002289
650    _2
$a progrese nemoci $7 D018450
650    _2
$a erbB receptory $x genetika $7 D066246
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gefitinib $x terapeutické užití $7 D000077156
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x genetika $x mortalita $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bratova, Monika $u Department of Respiratory Diseases, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Fischer, Ondrej $u Department of Respiratory Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Krejci, Jana $u Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic
700    1_
$a Koubkova, Leona $u Department of Pneumology, 2 Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Cernovska, Marketa $u Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic
700    1_
$a Hrnciarik, Michal $u Department of Pneumology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Zemanova, Milada $u Department of Oncology, 1 Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Coupkova, Helena $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Porzer, Bedrich $u Department of Respiratory Medicine and Tuberculosis, Medical faculty, Ostrava University, Ostrava, Czech Republic
700    1_
$a Dolezal, Daniel $u Department of Pneumology, Masaryk Hospital Usti nad Labem, Usti nad Labem, Czech Republic
700    1_
$a Tuzova, Tana $u Department of Oncology, Jihlava Hospital, Jihlava, Czech Republic
700    1_
$a Hurdalkova, Karolina $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Barinova, Magda $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Skrickova, Jana $u Department of Respiratory Diseases, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 41, č. 4 (2021), s. 2059-2065
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33813414 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100454 $b ABA008
999    __
$a ok $b bmc $g 1689854 $s 1139336
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 41 $c 4 $d 2059-2065 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace